<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886324</url>
  </required_header>
  <id_info>
    <org_study_id>PR2002</org_study_id>
    <nct_id>NCT03886324</nct_id>
  </id_info>
  <brief_title>POISE I Pilot Study</brief_title>
  <acronym>POISE</acronym>
  <official_title>Paclitaxel-Coated Balloon for the Treatment of Symptomatic Recurrent Benign Intestinal Stricture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GIE Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GIE Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      POISE I study is a feasibility study for evaluating the safety and efficacy of DCB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to determine the safety and effectiveness for drug coated balloon (DCB)&#xD;
      for treating intestinal strictures.&#xD;
&#xD;
      Up to 15 subjects are planned to be enrolled and treated with the study device at up to 5&#xD;
      clinical sites outside of US. Subjects will be followed up post-treatment to one year and&#xD;
      then annually for up to 5 years. The annual follow up after the first year is optional.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident of serious balloon dilation-related complications</measure>
    <time_frame>30 days</time_frame>
    <description>Perforation, bleeding requiring endoscopic or surgical interventions or blood transfusion, severe abdominal pain requiring medications, infection requiring hospitalization or IV antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>6 months</time_frame>
    <description>defined as subjects who were treated with GIE DCB achieved at least one scale improvement of the Endoscopic Obstructive Scale (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent subjects with improvement in Endoscopic Obstructive Scale (EOS)</measure>
    <time_frame>6 months</time_frame>
    <description>Analyzed by 1, 2, or 3 scale improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in obstructive symptoms using the Obstructive Symptom Score (OSS).</measure>
    <time_frame>30 days, 3 months, 6 months, and 12 months</time_frame>
    <description>The Obstructive Symptom Score (OSS) is a composite measure of the total number of days of obstructive abdominal pain and the severity over a fourteen-day period using a 5-point Likert scale. (1=no pain, 2=mild, 3=moderate, 4=severe, 5=unbearable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of repeated stricture dilation procedures</measure>
    <time_frame>30 days, 3 months, 6 months, and 12 months</time_frame>
    <description>Repeat dilation for stricture recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural technical success</measure>
    <time_frame>Time of procedure</time_frame>
    <description>Successful endoscopic passage followed by successful delivery of the drug-coated balloon to the stricture area without resistance, inflated balloon to the defined diameter, DCB withdraw after deflating balloon without device malfunction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Intestinal Stricture</condition>
  <arm_group>
    <arm_group_label>DCB Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stricture patients treated by DCB</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GIE Medical Drug Coated Balloon</intervention_name>
    <description>Stricture patients treated by DCB</description>
    <arm_group_label>DCB Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 80 years.&#xD;
&#xD;
          2. Subjects for whom the balloon dilation would be chosen in standard practice, and the&#xD;
             scope could not pass stricture.&#xD;
&#xD;
          3. Recurrent to plain balloon dilation with at least 2 previous balloon dilation or&#xD;
             stricturotomy sessions and recurrence of intestine obstructive symptoms/signs.&#xD;
&#xD;
          4. Symptoms of intestinal partial occlusion&#xD;
&#xD;
          5. Length of stenosis/stricture ≤ 7 cm&#xD;
&#xD;
          6. Up to 2 discrete strictures.&#xD;
&#xD;
          7. Ability to undergo periodic endoscopic follow-up.&#xD;
&#xD;
          8. Voluntary participation and provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding or plan to get pregnant in next 12 months.&#xD;
&#xD;
          2. Contraindication to endoscopy, anesthesia or deep sedation.&#xD;
&#xD;
          3. Malignant bowel stricture.&#xD;
&#xD;
          4. Extrinsic benign bowel stricture due to adhesion.&#xD;
&#xD;
          5. Stricture complicated with abscess, fistula, ulceration or associated with mesenteric&#xD;
             vessel thrombosis&#xD;
&#xD;
          6. More than 2 stenosis/stricture lesions.&#xD;
&#xD;
          7. Length of stenosis/stricture &gt; 7 cm.&#xD;
&#xD;
          8. Stricture not accessible by endoscopy.&#xD;
&#xD;
          9. Suspected perforation of the gastrointestinal tract&#xD;
&#xD;
         10. Acute bowel obstruction requiring urgent surgical intervention&#xD;
&#xD;
         11. Low rectal or anal strictures&#xD;
&#xD;
         12. Severe coagulation disorders (platelets &lt; 70000; INR &gt; 1.8).&#xD;
&#xD;
         13. Active systemic infection&#xD;
&#xD;
         14. Allergy to paclitaxel or any components of the delivery system.&#xD;
&#xD;
         15. Life expectancy of less than 12 months.&#xD;
&#xD;
         16. Drug abuse or on chronic steroid therapy for comorbidities.&#xD;
&#xD;
         17. Unwilling or unable to comply with the follow-up study requirements.&#xD;
&#xD;
         18. Lacking capacity to provide informed consent.&#xD;
&#xD;
         19. Concurrent medical condition that would affect the investigator's ability to evaluate&#xD;
             the patient's condition or could compromise patient safety.&#xD;
&#xD;
         20. Currently participation in another pre-market drug or medical device clinical study.&#xD;
&#xD;
         21. Chronic steroid use for any medical conditions unless subject is willing to undergo a&#xD;
             4-week washout and discontinue steroid use.&#xD;
&#xD;
         22. Currently requiring abdominal radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adventista Hospital</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

